Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?

Robertson, John F.R.; Sewell, Herb F.; Stewart, Marcia

doi:10.1016/s0140-6736(21)00455-4

Cited by 32 publications

(38 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The UK Government and Public Heath England, along with the general media, have seized these results to support and justify the UK policy of delaying the second dose of BNT162b2 to 12 weeks, but our concerns need to be addressed to ensure scientific rigour. As we have noted previously, 12 we have reason to believe delaying the second dose of BNT162b2 carries considerable personal and population risks.…”

Section: Covid-19 Vaccine Efficacy Data: Solid Enough To Delay Second Dose?mentioning

confidence: 79%

COVID-19 vaccine efficacy data: solid enough to delay second dose?

Robertson

Sewell

2021

The Lancet

Self Cite

View full text Add to dashboard Cite

Section: Covid-19 Vaccine Efficacy Data: Solid Enough To Delay Second Dose?mentioning

confidence: 79%

COVID-19 vaccine efficacy data: solid enough to delay second dose?

Robertson

Sewell

2021

The Lancet

Self Cite

View full text Add to dashboard Cite

“…Their retrospective analysis resulted in an 89% (95% CI, 52–97) efficacy supporting their delayed second dose decision. JVCI further concluded the study supporting 89% effectiveness continuing day 21 to day 85 without the second dose of the two-dose series [ 31 ]. Based on scientific literature, the BNT162b2 vaccination reported 52·4% efficacy on day 22, and 50–60% efficacy was summarized in Israel’s observational cohort studies during a similar time frame [ 31 ].…”

Section: Reviewmentioning

confidence: 99%

“…JVCI further concluded the study supporting 89% effectiveness continuing day 21 to day 85 without the second dose of the two-dose series [ 31 ]. Based on scientific literature, the BNT162b2 vaccination reported 52·4% efficacy on day 22, and 50–60% efficacy was summarized in Israel’s observational cohort studies during a similar time frame [ 31 ]. The suboptimal and partial immunity conferred by a single dosage and delayed the second dosage can put individuals and populations at risk from SARS-CoV-2 and its newly emerging variant strains [ 31 ].…”

Section: Reviewmentioning

confidence: 99%

“…Based on scientific literature, the BNT162b2 vaccination reported 52·4% efficacy on day 22, and 50–60% efficacy was summarized in Israel’s observational cohort studies during a similar time frame [ 31 ]. The suboptimal and partial immunity conferred by a single dosage and delayed the second dosage can put individuals and populations at risk from SARS-CoV-2 and its newly emerging variant strains [ 31 ]. The BNT162b2 two-dose vaccination series administered 21 days (3 weeks) apart have reported a 94% efficacy and should be maintained and supported to confer optimal immunity [ 31 ].…”

Section: Reviewmentioning

confidence: 99%

“…The suboptimal and partial immunity conferred by a single dosage and delayed the second dosage can put individuals and populations at risk from SARS-CoV-2 and its newly emerging variant strains [ 31 ]. The BNT162b2 two-dose vaccination series administered 21 days (3 weeks) apart have reported a 94% efficacy and should be maintained and supported to confer optimal immunity [ 31 ].…”

Section: Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization

Khehra¹,

Padda

Jaferi

et al. 2021

AAPS PharmSciTech

View full text Add to dashboard Cite

Vaccination development and production was an essential question for the prevention and global control of COVID-19. The strong support from governing authorities such as Operation Warp Speed and robust funding has led to the development and authorization of the tozinameran (BNT162b2) vaccine. The BNT162b2 vaccine is a lipid nanoparticle-encapsulated mRNA that encodes for SARS-CoV-2 spike protein, the main site for neutralizing antibodies. Once it binds with the host cells, the lipid nanoparticles enable the transfer of the RNA, causing S antigens’ expression of the SARS-CoV-2, conferring immunity. The vaccine is administered as a 2-dose regime 21 days apart for individuals 16 years and older. Pfizer-BioNTech’s BNT162b2 vaccine was the first candidate to receive FDA-Emergency Use Authorization (EUA) on December 11, 2020. During phase 2/3 clinical trials, 95% efficacy was reported among 37,706 participants over the age of 16 who received the BNT162b2 vaccination; additionally, 52% efficacy was noted 12 days following the administration of the first dose of BNT162b2, reflecting early protection of COVID-19. The BNT162b2 vaccine has exhibited 100% efficacy in clinical trials of adolescents between the ages of 12 and 15. Clinical trials in pregnant women and children under the age of 12 are expected to also exhibit promising results. This review article encompasses tozinameran (BNT162b2) vaccine journey, summarizing the BNT162b1 and BNT162b2 vaccines from preclinical studies, clinical trial phases, dosages, immune response, adverse effects, and FDA-EUA.

show abstract

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Gounant

Ferré

Soussi

et al. 2022

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer.Methods: SARS-CoV-2-spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed.Results: Overall, 306 patients, with a median age of 67.0 years (interquartile range: 58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day

show abstract

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?

Abstract: the Covid-19 Bereaved Families for Justice. UK COVID-19 public inquiry needed to learn lessons and save lives. Lancet 2020; 397: 177-80.

Cited by 32 publications

References 9 publications

COVID-19 vaccine efficacy data: solid enough to delay second dose?

COVID-19 vaccine efficacy data: solid enough to delay second dose?

Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Contact Info

Product

Resources

About